Vishangi Dave, MD
Hematology & Oncology · Sun City, AZNPI 1780947028
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $509 of the $697 with a category attached, or 73.0%. 8 manufacturers reported payments, led by Astellas Pharma US Inc at 27.0% of the total. That places this record below the midpoint for hematology & oncology clinicians in AZ, where the typical reported total is $6,870.
Across 9 payments — averaging $77.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$188
- Galvanize Therapeutics, Inc$152
- Verastem, Inc.$119
- Intuitive Surgical$97
- Covidien LP$87
- Bristol Myers Squibb$23
- plus $31 from 2 others
Across 12 payments — averaging $13.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$168
What the payments were for
- Food & beverage$50973%
- Education$18827%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 2 | $188 |
| Galvanize Therapeutics, Inc | 1 | $152 |
| Verastem, Inc. | 1 | $119 |
| Intuitive Surgical | 1 | $97 |
| Covidien LP | 1 | $87 |
| Bristol Myers Squibb | 1 | $23 |
| Bayer | 1 | $17 |
| Boehringer Ingelheim | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALIYA SYSTEM$152
- Copiktra$119
How this compares
$697 in reported general payments places this provider in the 20th percentile of 261 hematology & oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TabrectaCapmatinib Hydrochloride | 12 | $251,523 |
| TagrissoOsimertinib Mesylate | 15 | $219,003 |
| CalquenceAcalabrutinib Maleate | 12 | $186,223 |
| XtandiEnzalutamide | 12 | $128,089 |
| EliquisApixaban | 52 | $37,930 |
| XareltoRivaroxaban | 16 | $16,326 |
| Abiraterone Acetate | 12 | $2,224 |
| Ondansetron OdtOndansetron | 58 | $1,262 |
| Prochlorperazine Maleate | 57 | $856 |
| Letrozole | 27 | $667 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 36 | $420 |
| Potassium Chloride | 15 | $128 |
| Folic Acid | 11 | $121 |
| Prednisone | 31 | $119 |
| Levothyroxine Sodium | 17 | $108 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $188 | $128,08912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 261 hematology & oncology providers in Arizona.
Other hematology & oncology in Sun City
- Sujith KalmadiChandler$1.4M
- Jeffrey SchriberScottsdale$715K
- Javier MunozPhoenix$638K
- Tanios Bekaii-SaabScottsdale$527K
- Rajesh KukunoorScottsdale$499K
- Sumit MadanGilbert$422K
- Christopher ChenTucson$370K
- Rachna ShroffTucson$250K
- Govardhanan NagaiahGoodyear$222K
- Yousef ZakhariaScottsdale$214K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.